Tag: regenerative medicine company
March 13, 2019
NervGen Pharma Completes $10 Million Initial Public Offering; Shares to Commence Trading on TSX-V on March 15, 2019 – Symbol “NGEN”
NervGen Pharma Corp. ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of...
December 26, 2018
5 Top Medical Device News Stories of 2018
What was the top medical device news of 2018? Here's a list of our top headlines this year, according to... November 28, 2018
Pluristem to Present First Cohort Data from PLX-R18 Hematological Study at ASH Annual Meeting
Pluristem Therapeutics (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the company will... October 16, 2018
U.S. FDA Approves Cost Recovery for PLX-PAD under Expanded Access Program in the Treatment of Critical Limb Ischemia
Pluristem Therapeutics (Nasdaq:PSTI;TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, and WideTrial a privately-held third-party sponsor... September 25, 2018
Pluristem Therapeutics Announces FDA Orphan Drug Designation for PLX cell therapy
Pluristem Therapeutics (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the U.S. Food... September 18, 2018
Osiris Therapeutics Announces GrafixPL PRIME Launches October 1, 2018
Osiris Therapeutics (NASDAQ:OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announces... April 20, 2018